Michael Aldridge joins Codexis as SVP
Mr. Aldridge joins Codexis from Sirona Therapeutics Ltd., a privately held company he founded and served as President and Chief Executive Officer since 2015.
Previously he was Senior Vice President, Corporate Strategic Development for Questcor Pharmaceuticals, where he negotiated numerous strategic transactions and the sale of the company to Mallinckrodt Pharmaceuticals.
Prior to that, Mr. Aldridge served as Chief Executive Officer for two drug-development companies, including privately held Xenome Limited and publicly traded Peplin, Inc.
Before transitioning to those pharmaceutical industry roles, he held multiple investment banking positions, primarily in healthcare, at leading international financial firms including Wilson HTM Investment Group, Bear Stearns and Co., Volpe, Brown, Whelan and Company and SG Warburg Group.
Mr. Aldridge received a Master of Applied Finance from Macquarie University in Sydney, Australia and a BS with honors in Chemistry from the University of Canterbury in Christchurch, New Zealand.